Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016–2024)
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag308 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Helio S Sader und 5 weiteren Autor:innen. Beteiligte Einrichtung: Element Iowa City (JMI Laboratories), North Liberty, IA, USA. Hauptthemen laut MEDLINE: Azabicyclo Compounds, Aztreonam, Meropenem, Anti-Bacterial Agents. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie.
Abstract (Originalsprache)
Background
Resistance to ceftazidime/avibactam and meropenem/vaborbactam has been increasing among carbapenem-resistant Enterobacterales (CRE) in US hospitals recently. We evaluated the activity of aztreonam/avibactam and comparators against isolates that were not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam and against MBL-producing Enterobacterales.
Methods
A total of 80 927 Enterobacterales isolates were consecutively collected (one per patient) in 2016–2024 from 103 US medical centres and susceptibility tested by broth microdilution in a monitoring laboratory. Among those, 194 (0.24%) were not susceptible to ceftazidime/avibactam or meropenem/vaborbactam, 115 (0.14%) were not susceptible to both ceftazidime/avibactam and meropenem/vaborbactam, and 832 (1.0%) isolates were carbapenem resistant. These isolates were screened for carbapenemase (CBase) genes by WGS.
Results
Aztreonam/avibactam was active against 91.9% of ceftazidime/avibactam–non-susceptible isolates (n = 160), 94.0% of meropenem/vaborbactam–non-susceptible isolates (n = 149), 98.1% of CRE and 98.4% of MBL producers (n = 125). Cefiderocol retained activity against 78.8% of ceftazidime/avibactam–non-susceptible isolates, 83.2% of meropenem/vaborbactam–non-susceptible isolates, 94.7% of CRE and 82.1% of MBL producers. A CBase was identified in 159 (82.0%) of isolates not susceptible to ceftazidime/avibactam or meropenem/vaborbactam and in 683 (80.1%) of CREs. NDM (n = 114; 58.8% of isolates) was the most common CBase type among isolates not susceptible to ceftazidime/avibactam or meropenem/vaborbactam. Notably, an MBL was identified in 36.1% (73/202) of CRE collected in 2023–2024.
Conclusions
Aztreonam/avibactam demonstrated potent activity against isolates not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam as well as against CRE isolates, including MBL producers. The activities of other β-lactamase inhibitor combinations and cefiderocol were adversely affected by the alarming increase of MBL producers in some US hospitals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Element Iowa City (JMI Laboratories), North Liberty, IA, USA.
- AbbVie, North Chicago, IL, USA.
Förderung
- AbbVie
Zitieren
APA
Sader, H. S., Papp-Wallace, K. M., Kimbrough, J. H., Debabov, D., Mendes, R. E., & Castanheira, M. (2026). Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016–2024). Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag308
Vancouver
Sader HS, Papp-Wallace KM, Kimbrough JH, Debabov D, Mendes RE, Castanheira M. Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016–2024). Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag308
BibTeX
@article{Sader2026,
author = {Sader, Helio S and Papp-Wallace, Krisztina M and Kimbrough, John H and Debabov, Dmitri and Mendes, Rodrigo E and Castanheira, Mariana},
title = {Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016–2024)},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag308}
}
EUVIMED